| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
CC-90001 (CC90001; CC 90001) is a novel, potent and selective inhibitor of c-Jun N-terminal kinase (JNK) with potential anti-fibrotic activity. With IC50 values of 11 and 31 nM, it inhibits JNK1/2. CC-90001 has a low nanomolar JNK inhibitory potency, broad kinome selectivity, and the capacity to prevent cellular phosphorylation of the direct JNK substrate c-Jun. Regarding the physicochemical characteristics, CC-90001 also showed excellent systemic exposure after oral dosing, enabling in vivo efficacy studies and the choice of CC-90001 for clinical development. Patients with idiopathic pulmonary fibrosis are currently participating in Phase II clinical trials for CC-90001 (NCT03142191).
| Targets |
JNK1; JNK2
|
|---|---|
| ln Vitro |
In cell tests, CC-90001 suppresses LPS-induced c-jun phosphorylation with an EC50 of 480 nM [1]. JNK1 is 12.9 times more efficiently inhibited by CC-90001 than JNK2 is by the use of JNK1 and JNK2 knockout fibroblasts [1].
|
| ln Vivo |
A 48% reduction in collagen and a 53% reduction in alpha-smooth actin (α-SMA) in an adipose collagen model demonstrate that CC-90001 (3 mg/kg bid) inhibits the development of fibrosis [1]. CC-90001 lowers lung collagen extraction markers and disease-causing elevations in α-SMA to levels close to baseline in a home dust mite pulmonary fibrosis model [1].
|
| References | |
| Additional Infomation |
JNK1 Inhibitor BMS-986360 is an orally bioavailable, second-generation inhibitor of c-Jun N-terminal kinase 1 (JNK-1; JNK1; mitogen-activated protein kinase 8; MAPK8), with potential antineoplastic, anti-inflammatory and anti-fibrotic activities. Upon oral administration, JNK1 inhibitor BMS-986360 selectively targets, binds to and inhibits the activity of JNK1. Inhibition of JNK1-mediated mitogen-activated protein kinase (MAPK)-signaling pathways induces cell cycle arrest and apoptosis, decreases migration and invasion, and inhibits proliferation in JNK1-overexpressing cancer cells. Inhibition of JNK1-mediated pathways may also decrease fibrosis. JNK1, a member of the MAPK family and stress-activated protein, plays a role in the MAPK-mediated signaling pathway. It is often dysregulated in cancer cells and fibrosis.
|
| Molecular Formula |
C16H27N5O2
|
|---|---|
| Molecular Weight |
321.41788315773
|
| Exact Mass |
321.22
|
| Elemental Analysis |
C, 59.79; H, 8.47; N, 21.79; O, 9.96
|
| CAS # |
1403859-14-2
|
| Related CAS # |
1946833-77-7 (HCl);1403859-14-2;1946833-89-1;1946833-91-5 (mesylate); 1946833-97-1 (tartarte); 1946833-81-3 (lactate); 1946833-85-7 (citrate); 1946833-97-1 （fumarate);
|
| PubChem CID |
71237511
|
| Appearance |
White to yellow solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
412
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H]1CC[C@H](C[C@H]1O)NC2=NC(=NC=C2C(=O)N)NC(C)(C)C
|
| InChi Key |
QBBRJRLJWXRSHQ-CKYFFXLPSA-N
|
| InChi Code |
InChI=1S/C16H27N5O2/c1-9-5-6-10(7-12(9)22)19-14-11(13(17)23)8-18-15(20-14)21-16(2,3)4/h8-10,12,22H,5-7H2,1-4H3,(H2,17,23)(H2,18,19,20,21)/t9-,10-,12-/m1/s1
|
| Chemical Name |
2-(tert-butylamino)-4-[[(1R,3R,4R)-3-hydroxy-4-methylcyclohexyl]amino]pyrimidine-5-carboxamide
|
| Synonyms |
CC 90001; CC-90001; CC90001
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~388.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1112 mL | 15.5560 mL | 31.1119 mL | |
| 5 mM | 0.6222 mL | 3.1112 mL | 6.2224 mL | |
| 10 mM | 0.3111 mL | 1.5556 mL | 3.1112 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05625412 | Recruiting | Drug: BMS-986360 Drug: Docetaxel |
Advanced Solid Tumors | Bristol-Myers Squibb | December 9, 2022 | Phase 1 |
| NCT04655898 | Completed | Drug: [14C]CC-90001 | Healthy Volunteer | Celgene | December 16, 2020 | Phase 1 |
| NCT03742882 | Completed | Drug: CC-90001 | Hepatic Impairment | Celgene | December 6, 2018 | Phase 1 |
| NCT03958864 | Completed | Drug: CC-90001 | Healthy Volunteer | Celgene | April 4, 2019 | Phase 1 |
| NCT02510937 | Completed | Drug: CC-90001 | Pulmonary Fibrosis | Celgene | August 5, 2015 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
